Evolus +2% premarket on revenue beat

Evolus (EOLS) Q2 results: Revenues: $2.3M.

Net loss: ($37.6M) (-129.3%); loss/share: ($1.37) (-98.6%); Quick Assets: $99.9M (+7.2%).

The Company launched NEWTOX NOW $75 consumer coupon program on July 1, designed to accelerate Jeuveau conversion.

Evolus received a revised positive CHMP opinion for Nuceiva (prabotulinumtoxinA-xvfs) (branded as Jeuveau in U.S.) and now expect European approval in H2.

Shares are up 2% premarket.

Previously: Evolus EPS misses by $0.25, beats on revenue (Aug. 12)

https://seekingalpha.com/news/3490544-evolus-plus-2-percent-premarket-revenue-beat